Solventum Corp Completes Separation from 3M

TL;DR

Solventum is officially spun off from 3M as of Sept 1, 2025. It's a new independent company now.

AI Summary

Solventum Corporation, formerly 3M Health Care Co, completed its separation from 3M Company on September 1, 2025. This 8-K filing reports on the completion of this acquisition or disposition of assets, marking Solventum's transition to an independent entity. The company is incorporated in Delaware and its principal executive offices are located at 3M Center, Maplewood, Minnesota.

Why It Matters

This filing signifies the official independence of Solventum Corporation, a major player in the healthcare sector, from its former parent company 3M, impacting its strategic direction and financial reporting.

Risk Assessment

Risk Level: medium — The separation of a large business unit can introduce operational and financial risks as the new entity establishes its independent infrastructure and market position.

Key Players & Entities

• Solventum Corporation (company) — Registrant
• 3M Company (company) — Former Parent Company
• 3M Health Care Co (company) — Former Name
• September 1, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• Maplewood, Minnesota (location) — Principal Executive Offices

FAQ

From the Filing

0001964738-25-000078.txt : 20250902 0001964738-25-000078.hdr.sgml : 20250902 20250902080114 ACCESSION NUMBER: 0001964738-25-000078 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250901 ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250902 DATE AS OF CHANGE: 20250902 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Solventum Corp CENTRAL INDEX KEY: 0001964738 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 922008841 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41968 FILM NUMBER: 251283010 BUSINESS ADDRESS: STREET 1: C/O 3M COMPANY STREET 2: 3M CENTER, BUILDING 275-6W-02 CITY: ST. PAUL STATE: MN ZIP: 55144-1000 BUSINESS PHONE: 651-733-1110 MAIL ADDRESS: STREET 1: C/O 3M COMPANY STREET 2: 3M CENTER, BUILDING 275-6W-02 CITY: ST. PAUL STATE: MN ZIP: 55144-1000 FORMER COMPANY: FORMER CONFORMED NAME: 3M Health Care Co DATE OF NAME CHANGE: 20230203 8-K 1 solv-20250901.htm 8-K solv-20250901 FALSE 0001964738 0001964738 2025-09-01 2025-09-01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 1, 2025 SOLVENTUM CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware File No. 001-41968 92-2008841 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 3M Center, Building 275-6W 2510 Conway Avenue East , Maplewood , Minnesota 55144 (Address of Principal Executive Offices) (Zip Code) (Registrant’s Telephone Number, Including Area Code) ( 651 ) 733-1110 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, Par Value $.01 Per Share SOLV New York Stock Exchange Securities registered pursuant to section 12(g) of the Act: None Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company      ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the exchange Act.     ☐ Item 2.01. Completion of Acquisition or Disposition of Assets. On February 25, 2025, Solventum Corporation, a Delaware corporation (“Solventum”) and Thermo Fisher Scientific Inc., a Delaware corporation (“Buyer”), entered into a Transaction Agreement, pursuant to which Buyer agreed to acquire from Solventum certain assets and liabilities related to Solventum’s purification and filtration business. On June 25, 2025, Solventum and Buyer entered into an Amen